AU Patent

AU2013329421A1 — Combination therapies and uses for treatment of demyelinating disorders

Assigned to Biogen MA Inc · Expires 2015-04-30 · 11y expired

What this patent protects

Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments, the methods and compositions described he…

USPTO Abstract

Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments, the methods and compositions described herein include a reparative agent (

Drugs covered by this patent

Patent Metadata

Patent number: AU2013329421A1
Jurisdiction: AU
Classification: —
Expires: 2015-04-30
Drug substance claim: No
Drug product claim: No
Assignee: Biogen MA Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.